Several early clinical trials explored PD-L1 as a surrogate of ICB response; though given a multitude of reagents and antibodies used across several assays, the reliability of PD-L1 as a biomarker of response remains variable, and PD-L1 expression status has varied in its prediction of melanoma response to ICB (105). Here, CD274 is linked to melanoma.